{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:33:14Z","timestamp":1780407194098,"version":"3.54.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009594","name":"University of P\u00e9cs","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009594","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Clinical trials demonstrate the short-term efficacy of dual CFTR modulators, but long-term real-world data is limited. We aimed to investigate the effects of 24-month lumacaftor\/ivacaftor (LUM\/IVA) therapy in pediatric CF patients (pwCF). This observational study included pwCF homozygous for F508del mutation treated between 2021 and 2023. We report data for the first 24\u00a0months from therapy initiation. Variables were analyzed separately for ages 2\u20135, 6\u201311, and over 12. Data from 49 pwCF (median age: 9.3\u00a0years (5.5\u201314.2)) showed that ppFEV1 values after a transient increase at 12\u00a0months, decreased from 102% (82\u2013114) at baseline to 87% (74\u201396)\u00a0at 24\u00a0months. The decrease was more pronounced with higher initial ppFEV1. Median sweat chloride concentration decreased from 75\u00a0mmol\/L (69\u201382) to 57\u00a0mmol\/L (43\u201370) without any association with respiratory function change. Median BMI\u00a0<jats:italic>z<\/jats:italic>-score increased from\u2009\u2212\u20090.81 (\u2212\u20091.37\u20130.49) to\u2009\u2212\u20090.39 (\u2212\u20090.88 to \u2009\u2212\u20090.04) (<jats:italic>p<\/jats:italic>\u2009=\u20090.288), and the proportion of underweight and overweight children decreased.\u00a0Skeletal muscle mass remained stable, while fat mass significantly increased (<jats:italic>p<\/jats:italic>\u2009=\u20090.011). Fecal elastase levels improved, especially among younger patients. These findings underscore the potential benefits of early initiation of CFTR modulator therapy in pediatric CF patients, highlighting improvements in nutritional status and pancreatic function.<\/jats:p>","DOI":"10.1038\/s41598-025-86010-1","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T09:22:00Z","timestamp":1737105720000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Body composition changes and clinical outcomes in pediatric cystic fibrosis during 24\u00a0months of lumacaftor ivacaftor therapy based on real-world data"],"prefix":"10.1038","volume":"15","author":[{"given":"Marcell","family":"Imrei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienn F.","family":"K\u00e9ri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"G\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildik\u00f3","family":"G\u00f6nczi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Mel\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9va","family":"Kosaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botond","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"P\u00e9terfia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kl\u00e1ra","family":"Vass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6ngyi","family":"Sz\u00e9kely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klementina","family":"Ocskay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"P\u00e1rniczky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"86010_CR1","volume":"54","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi, V. & Farrell, P. M. Update on advances in cystic fibrosis towards a cure and implications for primary care clinicians. Curr. Probl. Pediatr. Adolesc. Health Care 54, 101637 (2024).","journal-title":"Curr. Probl. Pediatr. Adolesc. Health Care"},{"key":"86010_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S2213-2600(17)30215-1","volume":"5","author":"F Ratjen","year":"2017","unstructured":"Ratjen, F. et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6\u201311 years with cystic fibrosis homozygous for F508del-CFTR: A randomised, placebo-controlled phase 3 trial. Lancet Respir. Med. 5, 557\u2013567 (2017).","journal-title":"Lancet Respir. Med."},{"key":"86010_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","volume":"206","author":"JH Rayment","year":"2022","unstructured":"Rayment, J. H. et al. A phase 3, open-label study of lumacaftor\/ivacaftor in children 1 to less than 2 years of age with cystic fibrosis homozygous for F508del-CFTR. Am. J. Respir. Crit. Care Med. 206, 1239\u20131247 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"86010_CR4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S2213-2600(18)30460-0","volume":"7","author":"JJ McNamara","year":"2019","unstructured":"McNamara, J. J. et al. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2\u20135 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. Lancet Respir. Med. 7, 325\u2013335 (2019).","journal-title":"Lancet Respir. Med."},{"key":"86010_CR5","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S2213-2600(21)00069-2","volume":"9","author":"JE Hoppe","year":"2021","unstructured":"Hoppe, J. E. et al. Long-term safety of lumacaftor\u2013ivacaftor in children aged 2\u20135 years with cystic fibrosis homozygous for the F508del-CFTR mutation: A multicentre, phase 3, open-label, extension study. Lancet Respir. Med. 9, 977\u2013988 (2021).","journal-title":"Lancet Respir. Med."},{"key":"86010_CR6","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S2213-2600(20)30517-8","volume":"9","author":"MA Chilvers","year":"2021","unstructured":"Chilvers, M. A. et al. Long-term safety and efficacy of lumacaftor\u2013ivacaftor therapy in children aged 6\u201311 years with cystic fibrosis homozygous for the F508del-CFTR mutation: A phase 3, open-label, extension study. Lancet Respir. Med. 9, 721\u2013732 (2021).","journal-title":"Lancet Respir. Med."},{"key":"86010_CR7","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1056\/NEJMoa1409547","volume":"373","author":"CE Wainwright","year":"2015","unstructured":"Wainwright, C. E. et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med 373, 220\u2013231 (2015).","journal-title":"N Engl J Med"},{"key":"86010_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","volume":"5","author":"MW Konstan","year":"2017","unstructured":"Konstan, M. W. et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): A phase 3, extension study. Lancet Respir. Med. 5, 107\u2013118 (2017).","journal-title":"Lancet Respir. Med."},{"key":"86010_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.nut.2015.10.012","volume":"32","author":"JA Alvarez","year":"2016","unstructured":"Alvarez, J. A., Ziegler, T. R., Millson, E. C. & Stecenko, A. A. Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity. Nutrition 32, 447\u2013452 (2016).","journal-title":"Nutrition"},{"key":"86010_CR10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0740","volume":"5","author":"R Nagy","year":"2022","unstructured":"Nagy, R. et al. Association of body mass index with clinical outcomes in patients with cystic fibrosis: A systematic review and meta-analysis. JAMA Netw. Open 5, e220740 (2022).","journal-title":"JAMA Netw. Open"},{"key":"86010_CR11","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1016\/j.clnu.2023.10.015","volume":"42","author":"C Knott-Torcal","year":"2023","unstructured":"Knott-Torcal, C. et al. A prospective study to assess the impact of a novel CFTR therapy combination on body composition in patients with cystic fibrosis with F508del mutation. Clin. Nutr. 42, 2468\u20132474 (2023).","journal-title":"Clin. Nutr."},{"key":"86010_CR12","doi-asserted-by":"publisher","first-page":"1157459","DOI":"10.3389\/fphar.2023.1157459","volume":"14","author":"M Mouzaki","year":"2023","unstructured":"Mouzaki, M. et al. Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass. Front. Pharmacol. 14, 1157459 (2023).","journal-title":"Front. Pharmacol."},{"key":"86010_CR13","doi-asserted-by":"publisher","first-page":"00203","DOI":"10.1183\/23120541.00203-2020","volume":"7","author":"SJ King","year":"2021","unstructured":"King, S. J. et al. Lumacaftor\/ivacaftor-associated health stabilisation in adults with severe cystic fibrosis. ERJ Open Res. 7, 00203\u201302020 (2021).","journal-title":"ERJ Open Res."},{"key":"86010_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association Declaration of Helsinki","year":"2013","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 310, 2191 (2013).","journal-title":"JAMA"},{"key":"86010_CR15","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpeds.2016.09.064","volume":"181","author":"PM Farrell","year":"2017","unstructured":"Farrell, P. M. et al. Diagnosis of cystic fibrosis: Consensus guidelines from the cystic fibrosis foundation. J. Pediatr. 181, S4\u2013S15 (2017).","journal-title":"J. Pediatr."},{"key":"86010_CR16","unstructured":"European Medicines Agency. Orkambi: EPAR - Product Information. (2024)."},{"key":"86010_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.clnu.2023.12.017","volume":"43","author":"M Wilschanski","year":"2024","unstructured":"Wilschanski, M. et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin. Nutr. 43, 413\u2013445 (2024).","journal-title":"Clin. Nutr."},{"key":"86010_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/jfmk4020023","volume":"4","author":"J Antonio","year":"2019","unstructured":"Antonio, J. et al. Comparison of dual-energy X-ray absorptiometry (DXA) versus a multi-frequency bioelectrical impedance (InBody 770) device for body composition assessment after a 4-week hypoenergetic diet. JFMK 4, 23 (2019).","journal-title":"JFMK"},{"key":"86010_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgast-2021-000643","volume":"8","author":"ME Phillips","year":"2021","unstructured":"Phillips, M. E. et al. Consensus for the management of pancreatic exocrine insufficiency: UK practical guidelines. BMJ Open Gastroenterol. 8, e000643 (2021).","journal-title":"BMJ Open Gastroenterol."},{"key":"86010_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","volume":"2","author":"TWR Lee","year":"2003","unstructured":"Lee, T. W. R., Brownlee, K. G., Conway, S. P., Denton, M. & Littlewood, J. M. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J. Cyst. Fibros. 2, 29\u201334 (2003).","journal-title":"J. Cyst. Fibros."},{"key":"#cr-split#-86010_CR21.1","unstructured":"Flegal, K. M. & Cole, T. J. Construction of LMS parameters for the Centers for Disease Control and Prevention 2000 growth charts. National health statistics reports"},{"key":"#cr-split#-86010_CR21.2","unstructured":"no 63. Hyattsville, MD: National Center for Health Statistics. (2013)."},{"key":"86010_CR22","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1556\/650.2022.32655","volume":"163","author":"A De\u00e1k","year":"2022","unstructured":"De\u00e1k, A. et al. A magyar Cyst\u00e1s Fibrosis Regiszter genetikai rev\u00edzi\u00f3ja. Orvosi Hetilap 163, 2052\u20132059 (2022).","journal-title":"Orvosi Hetilap"},{"key":"86010_CR23","unstructured":"Zolin, A. et al. ECFSPR Annual Report 2021. (2023)."},{"key":"86010_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.744705","volume":"9","author":"S Bui","year":"2021","unstructured":"Bui, S. et al. Long-term outcomes in real life of lumacaftor-ivacaftor treatment in adolescents with cystic fibrosis. Front. Pediatr. 9, 744705 (2021).","journal-title":"Front. Pediatr."},{"key":"86010_CR25","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.3390\/molecules27165324","volume":"27","author":"E Moliteo","year":"2022","unstructured":"Moliteo, E. et al. Cystic fibrosis and oxidative stress: The role of CFTR. Molecules 27, 5324 (2022).","journal-title":"Molecules"},{"key":"86010_CR26","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/genes14020449","volume":"14","author":"A Giallongo","year":"2023","unstructured":"Giallongo, A. et al. Effects of elexacaftor\/tezacaftor\/ivacaftor on cardiorespiratory polygraphy parameters and respiratory muscle strength in cystic fibrosis patients with severe lung disease. Genes 14, 449 (2023).","journal-title":"Genes"},{"key":"86010_CR27","doi-asserted-by":"publisher","first-page":"2400004","DOI":"10.1183\/13993003.00004-2024","volume":"64","author":"M Stahl","year":"2024","unstructured":"Stahl, M. et al. Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles. Eur. Respir. J. 64, 2400004 (2024).","journal-title":"Eur. Respir. J."},{"key":"86010_CR28","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/jpm11121376","volume":"11","author":"D Muilwijk","year":"2021","unstructured":"Muilwijk, D. et al. Prediction of real-world long-term outcomes of people with CF homozygous for the F508del mutation treated with CFTR modulators. JPM 11, 1376 (2021).","journal-title":"JPM"},{"key":"86010_CR29","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","volume":"18","author":"SD Sagel","year":"2021","unstructured":"Sagel, S. D. et al. Clinical effectiveness of lumacaftor\/ivacaftor in patients with cystic fibrosis homozygous for F508del-CFTR. A Clinical Trial. Ann. ATS 18, 75\u201383 (2021).","journal-title":"Ann. ATS"},{"key":"86010_CR30","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.jcf.2020.05.004","volume":"20","author":"BL Aalbers","year":"2021","unstructured":"Aalbers, B. L. et al. Females with cystic fibrosis have a larger decrease in sweat chloride in response to lumacaftor\/ivacaftor compared to males. J. Cyst. Fibros. 20, e7\u2013e11 (2021).","journal-title":"J. Cyst. Fibros."},{"key":"86010_CR31","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jcf.2018.12.011","volume":"18","author":"A Masson","year":"2019","unstructured":"Masson, A. et al. Predictive factors for lumacaftor\/ivacaftor clinical response. J. Cyst. Fibros. 18, 368\u2013374 (2019).","journal-title":"J. Cyst. Fibros."},{"key":"86010_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","volume":"201","author":"P-R Burgel","year":"2020","unstructured":"Burgel, P.-R. et al. Real-life safety and effectiveness of lumacaftor-ivacaftor in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 201, 188\u2013197 (2020).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"86010_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jcf.2021.06.002","volume":"21","author":"P Reix","year":"2022","unstructured":"Reix, P. et al. Real-world assessment of LCI following lumacaftor-ivacaftor initiation in adolescents and adults with cystic fibrosis. J. Cyst. Fibros. 21, 155\u2013159 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"86010_CR34","doi-asserted-by":"publisher","first-page":"1130790","DOI":"10.3389\/fped.2023.1130790","volume":"11","author":"M Gaschignard","year":"2023","unstructured":"Gaschignard, M. et al. Nutritional impact of CFTR modulators in children with cystic fibrosis. Front. Pediatr. 11, 1130790 (2023).","journal-title":"Front. Pediatr."},{"key":"86010_CR35","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1002\/ppul.26797","volume":"59","author":"C Dress","year":"2024","unstructured":"Dress, C. et al. Body composition in children with cystic fibrosis treated with CFTR modulators versus modulator na\u00efve individuals. Pediatric Pulmonol. 59, 805\u2013808 (2024).","journal-title":"Pediatric Pulmonol."},{"key":"86010_CR36","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.jcf.2024.02.004","volume":"23","author":"C Kim","year":"2024","unstructured":"Kim, C. et al. Effectiveness of lumacaftor\/ivacaftor initiation in children with cystic fibrosis aged 2 through 5 years on disease progression: Interim results from an ongoing registry-based study. J. Cyst. Fibros. 23, 436\u2013442 (2024).","journal-title":"J. Cyst. Fibros."},{"key":"86010_CR37","doi-asserted-by":"crossref","unstructured":"Sheikh, S., Zemel, B. S., Stallings, V. A., Rubenstein, R. C. & Kelly, A. Body composition and pulmonary function in cystic fibrosis. Front. Pediatr. 2, (2014).","DOI":"10.3389\/fped.2014.00033"},{"key":"86010_CR38","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/j.jcf.2023.06.003","volume":"22","author":"JK Tran","year":"2023","unstructured":"Tran, J. K., Ooi, C. Y., Blazek, K. & Katz, T. Body composition and body mass index measures from 8 to 18 years old in children with cystic fibrosis. J. Cyst. Fibros. 22, 851\u2013856 (2023).","journal-title":"J. Cyst. Fibros."},{"key":"86010_CR39","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jcf.2023.09.005","volume":"22","author":"KG Stephenson","year":"2023","unstructured":"Stephenson, K. G. et al. Changes in fecal elastase-1 following initiation of CFTR modulator therapy in pediatric patients with cystic fibrosis. Journal of Cystic Fibrosis 22, 996\u20131001 (2023).","journal-title":"Journal of Cystic Fibrosis"},{"key":"86010_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.5364","volume":"10","author":"T Fuchs","year":"2022","unstructured":"Fuchs, T., Appelt, D., Niedermayr, K. & Ellemunter, H. REAL-world clinical effectiveness of ivacaftor therapy in the first 24 months in two infants with cystic fibrosis and different gating mutations\u2014A case report. Clin. Case Rep. 10, e05364 (2022).","journal-title":"Clin. Case Rep."},{"key":"86010_CR41","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jcf.2021.07.018","volume":"21","author":"D Drummond","year":"2022","unstructured":"Drummond, D. et al. Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR. J. Cyst. Fibros. 21, 212\u2013219 (2022).","journal-title":"J. Cyst. Fibros."},{"key":"86010_CR42","doi-asserted-by":"publisher","first-page":"1327958","DOI":"10.3389\/fmolb.2023.1327958","volume":"10","author":"A Castaldo","year":"2024","unstructured":"Castaldo, A. et al. One year of treatment with elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis homozygous for the F508del mutation causes a significant increase in liver biochemical indexes. Front. Mol. Biosci. 10, 1327958 (2024).","journal-title":"Front. Mol. Biosci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86010-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86010-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T09:22:11Z","timestamp":1737105731000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-86010-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["86010"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-86010-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"23 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2247"}}